Varicella-zoster virus infections

被引:6
作者
Lilie, HM [1 ]
Wassilew, SW [1 ]
机构
[1] Klinikum Krefeld, Dermatol Klin, D-47805 Krefeld, Germany
来源
HAUTARZT | 2004年 / 55卷 / 09期
关键词
varicella-zoster virus; varicella; herpes zoster; antiviral therapy;
D O I
10.1007/s00105-004-0789-1
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The primary infection with varicella-zoster virus (VZV) is manifest clinically as varicella. It is a common very contagious disease, normally appearing in childhood. VZV is a ubiquitous virus with a high prevalence. Clinically it is characterized by pleomorphic skin lesions. Normally antiviral therapy is necessary only in severe cases, in adults or in immunosuppressed patients. Herpes zoster, also caused by (VZV), is a neurocutaneous disease representing endogenous relapse of primary varicella infection. Herpes zoster is characterized by lesions concentrated in the innervation region of a cranial or spinal nerve. One of the most feared manifestations of herpes zoster is pain. Several antiviral drugs are approved and many studies have shown that antiviral therapy, started early in the course of disease, can significantly reduce risk and duration of postherpetic neuralgia in elderly patients. Therefore, antiviral therapy in combination with an adequate pain management should be given to all elderly patients as soon as herpes zoster is diagnosed.
引用
收藏
页码:831 / +
页数:10
相关论文
共 66 条
[21]   Herpes zoster guideline of the German Dermatology Society (DDG) [J].
Gross, G ;
Schöfer, H ;
Wassilew, S ;
Friese, K ;
Timm, A ;
Guthoff, R ;
Pau, HW ;
Malin, JP ;
Wutzler, P ;
Doerr, HW .
JOURNAL OF CLINICAL VIROLOGY, 2003, 26 (03) :277-289
[22]  
Gross G, 2003, DERMATOLOGISCHE INFE, P110
[23]  
HEIDL M, 1990, Z KLIN MED, V45, P1259
[24]  
Hope-Simpson R E, 1975, J R Coll Gen Pract, V25, P571
[25]  
HUFF JC, 1993, J MED VIROL, P93
[26]  
JOHNSON R, 1995, J INFECTION, V30, P193
[27]   Varicella vaccine for immunocompromised children: Results of collaborative studies in the United States and Canada [J].
LaRussa, P ;
Steinberg, S ;
Gershon, AA .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 :S320-S323
[28]   Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: Duration of booster effect [J].
Levin, MJ ;
Barber, D ;
Goldblatt, E ;
Jones, M ;
LaFleur, B ;
Chan, C ;
Stinson, D ;
Zerbe, GO ;
Hayward, AR .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 :S109-S112
[29]  
Levin MJ, 2001, ARCH VIR S, V17, P151
[30]  
Liesegang TJ, 1999, MAYO CLIN PROC, V74, P983